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Abstract
Background: Concerns have risen regarding the potential side effects of clinical exposure of the pediatric
population to inhalational anesthetics, and how they might impact cognitive, learning, and memory functions.
However, neither the mechanisms of anesthetic cytotoxicity, nor potential protective strategies, have yet been fully
explored. In this study, we examined whether two of the most commonly used inhalational anesthetics, sevoflurane
and desflurane, affect neuronal viability and synaptic network assembly between cultured rat cortical neurons.
Results: Primary rat cortical neuron cultures were exposed to equipotent sevoflurane or desflurane for 1 hour.
Neuron viability, synaptic protein expression, mitochondrial morphology, and neurite growth were assayed with
immunostaining and confocal microscopy techniques. The effects of anesthetics on the functional development of
neural networks were evaluated with whole-cell patch clamp recordings of spontaneous synaptic currents. Our
results demonstrate that an acute exposure to sevoflurane and desflurane inhibits the development of neurite
processes, impacts the mitochondria, and compromises synaptic proteins - concomitant with a reduction in
synaptic function in mature networks. Interestingly, pretreatment of neurons with a mitochondrial division inhibitor
(Mdivi-1) not only protected mitochondria integrity but also played a protective role against anesthetic-induced
structural and functional neurotoxicity.
Conclusions: We show that Mdivi-1 likely plays a protective role against certain harmful effects of general
anesthetics on primary rat neuronal cultures. In addition, Mdivi-1 alone plays a direct role in enhancing growth and
modulating synaptic activity. This study highlights the importance of further study into possible protective agents
against anesthetic neurotoxicity.
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Background
General anesthetics are required for surgical procedures.
Whereas our understanding of various modes of
anesthetic actions has improved significantly [1], their
use in younger children has brought to light significant
long-term side effects as they pertain to compromised
learning and memory functions [2]. These agents act
mainly as agonists of gamma-aminobutyric acid (GABA)
receptors, antagonists of the N-methyl-D-aspartate
(NMDA) receptors, or modulators of the fluidity of
plasma membrane [3].
The potential neurotoxic effects of anesthesia were
first brought to light with the observation that blockade
of the NMDA-receptor induces apoptotic neurodegener-
ation of the developing brain [4]. Extensive epidemio-
logical studies have since questioned the safety of
general anesthesia in young children whose brains are
undergoing rapid development [2]. A clear consensus in
the field vis-à-vis the potential target sites for anesthetic
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toxicity have yet to be reached-due mainly to myriad
confounding variables. Whereas it is becoming increas-
ingly clear that either single or repeated exposure of
children to anesthetics impacts their cognitive functions
including learning and memory, the mechanisms remain
poorly defined. Since learning and memory rely on syn-
aptic integrity and plasticity [5], it stands to reason that
inhalational anesthetics affect synaptic assembly in chil-
dren, however this cannot be tested experimentally. Ani-
mal models involving either in vivo or in vitro
techniques have now shown that general anesthetics in-
duce neuroapoptosis, leading to neurodevelopmental de-
lays or cognitive disabilities in later life [6]. For instance,
administration of propofol to neonatal rats [7], and rhe-
sus macaques [8] increased cell death in the cortex and
hippocampus, which led to long-term learning and
memory deficits. Similar results have emerged whereby
other general anesthetics were shown to impact neuro-
genesis, proliferation, and differentiation [9, 10]. How-
ever, the data demonstrating the acute effects of
anesthetic exposure to synaptic architecture and func-
tion in developing networks is still lacking-specifically
for sevoflurane and desflurane.
In this study, we hypothesized that exposure of imma-
ture neurons to clinically relevant doses of sevoflurane
and desflurane will negatively impact neuronal viability
and synaptic function, and that these effects may involve
compromised synaptic proteins and mitochondrial integ-
rity. To test this hypothesis, we used cultured rat cortical
neurons, which were exposed to sevoflurane and desflur-
ane, and their cytotoxic effects were investigated. We
next sought strategies that might curtail anesthetic-
mediated cytotoxicity in an in vitro cortical neuron
model.
Results
Desflurane and sevoflurane inhibited neurite outgrowth
and reduced cell survival in immature rat cortical neurons
We exposed rat cortical neurons to equipotent, physio-
logically relevant doses of sevoflurane and desflurane.
Specifically, cortical cultures were exposed to clinically
relevant concentrations (roughly 0.5 minimum alveolar
concentration equivalent) of either sevoflurane (1.3 %)
or desflurane (4.3 %) [11, 12].
To qualitatively examine how anesthetics may impact
neurite growth and viability, neonatal neurons were ex-
posed for 1 h to medical air (alone, control) or medical
air mixed with sevoflurane or desflurane and maintained
in culture for 3 days. Phase contrast images were ac-
quired on day 3 to evaluate early neuronal morphology.
Figure 1a shows a culture dish grown under control con-
ditions (medical air only), yielding a healthy population
of cells with extensive neurite branches, processes, and
overlapping neurites (indicated by a circle). Although
cells exposed to sevoflurane (Fig. 1b) and desflurane
(Fig. 1c) developed neurites, their total length and num-
ber of branches appeared reduced (Fig. 1a). Note that
certain cell bodies of sevoflurane and desflurane treated
neurons appeared to exhibit vacuolation, indicative of
neuronal degeneration and apoptosis (indicated by aster-
isks, Fig. 1b, c).
To validate increases in the incidence of cell death, we
next performed a live/dead cell assay. Specifically, con-
trol and anesthetic treated cells were maintained in cul-
ture for 3 days. Neurons were incubated and stained
with green-fluorescent calcein-AM for 15 mins to indi-
cate intracellular esterase activity (live cells), and red-
fluorescent ethidium homodimer-1 to determine damage
to plasma membrane integrity (dead cells) (Fig. 1d–f ).
To quantify these effects, neurons were counted based
on a random selection of minimum of three areas
(88,090 μm2) from each dish for at least four replicate
dishes. The mean value of cell viability reflected by the
percentage of viable cells (calcein-AM positive staining)
was calculated. Cells exposed to sevoflurane (85 ± 2 %
alive, n = 17 areas, p > 0.05) did not show a difference (p
= 0.84) in cell viability compared to control cells (86 ±
2 % alive, n = 16 areas), whereas those subjected to an
equipotent dose of desflurane (67 ± 3 % alive, n = 14
areas) revealed a significant reduction in cell viability (p
< 0.0001) (Fig. 1g).
Both sevoflurane and desflurane perturbed the
expression of synaptic proteins
Whereas cell survival and membrane integrity are funda-
mental to the development of functional neural net-
works, cell-cell or neurite-neurite contacts form the
basis for the development and maturation of synaptic
structures. These contacts are maintained by a variety of
proteins. To assess whether inhalational anesthetics
affect the level and/or localization of two critical synap-
tic proteins, such as the presynaptic vesicle protein,
synaptophysin, and the postsynaptic density protein,
PSD-95 [13], day 0 cells were exposed to medical air
only (serving as a control, Fig. 2a–c), medical air mixed
with sevoflurane (Fig. 2d–f ) and desflurane (Fig. 2g–i)
for 1 hour. Neurons were maintained in culture for
10 days to allow for the full development of a mature
synaptic network, a commonly used time point in pri-
mary culture [14].
Quantitative, immunochemical analysis demonstrated
that the controls exposed to the medical air alone devel-
oped intricate synaptic circuitries represented by a high
degree of PSD-95 expression and punctate expression of
presynaptic synaptophysin, as well as intense staining for
both proteins (Fig. 2a–c). Treatment with sevoflurane
and desflurane appeared to have reduced the incidence
of punctate expression of synaptophysin, marking a
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potential decrease in the number of synapses between
these neurons (Fig. 2d, g). To quantify this, we counted
the number of PSD-95/synaptophysin positive puncta
per length of the selected neurite under each condition.
Neurites were a heterogenous mix of primary and sec-
ondary branches identified as filamentous projections
from either a neuron’s cell body or another neurite, re-
spectively. Multiple neurites were analyzed from each
cell and at least six cells were analyzed in each condi-
tion. These neurites ranged in length from 16.8 μm to
97.7 μm. Indeed, we observed a significant reduction in
the number of puncta per μm of neurite as a result of
anesthetic treatment (ANOVA F2,49 = 7.015, p = 0.0021)
(Fig. 2j) in both sevoflurane (0.12 ± 0.01 puncta/μm, n =
20 neurites, p < 0.01) and desflurane (0.11 ± 0.01 puncta/
μm, n = 14 neurites, p < 0.01) as compared to control
neurons (0.18 ± 0.02 puncta/μm, n = 18 neurites). Fur-
thermore, we measured the mean fluorescence intensity
of synaptophysin and PSD-95 in separate images taken
with similar cell densities (800–1000 cells/mm2) under
control and anesthetic-treated conditions. Our data
demonstrated that the fluorescence intensity (Fig. 2k),
relative to the control, of presynaptic synaptophysin was
significantly reduced by anesthetic treatment after ana-
lyzing with ANOVA (F2,28 = 10.10, p = 0.005). However,
post-hoc tests revealed a significant difference only with
desflurane treatment (0.68 ± 0.03, p = 0.0014, n = 6), yet
not with sevoflurane (0.84 ± 0.06, n = 7, p = 0.11). PSD-
95 was not significantly reduced by either desflurane
(0.83 ± 0.03, p = 0.1, n = 6) or sevoflurane (0.88 ± 0.06, p
= 0.35, n = 7).
Sevoflurane and desflurane impacted neuronal
mitochondria and these effects were inhibited by Mdivi-1
All aspects of neuronal growth and synaptic function rely
on energy derived from mitochondria. Therefore, we ex-
amined mitochondrial morphology with MitoTracker
Red, a specific mitochondrial marker with a mitochondrial
membrane potential dependent uptake, and whether pre-
treatment with a mitochondrial protective agent, Mdivi-1,
can help restore any deficits. As shown in Fig. 3a, mito-
chondria in control neurons exhibit typical rounded rod
Fig. 1 Sevoflurane and desflurane inhibited neurite outgrowth and compromised neuronal viability of rat cortical neurons. (a–c) Phase contrast
images taken at day 3 of random areas of neurons exposed to medical air only (a), or equipotent sevoflurane (b, 1.3 %) and desflurane (c, 4.3 %).
Circled areas indicate neurons and neurite overlap, and asterisks indicate neurons with the vacuolation typical of apoptosis. (d–f) Confocal images
were taken on day 3 stained for live cells with Calcein-AM (green) and ethidium homodimer (red) for dead cells. (g) Quantification of live/dead
cells by counting all cells positive for Calcein-AM or ethidium homodimer staining within at least three given areas of at least four replicate dishes.
Scale bar 25 μm (a–c), 50 μm (d–f).
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shapes (intermediate). However, in sevoflurane and des-
flurane treated neurons, mitochondria appeared fragmen-
ted within the cell body, and were scarcely present in the
neurites (indicated by arrows) (Fig. 3b, c). Some cells ex-
hibited fused mitochondrial morphology (Fig. 3e). Two-
way ANOVA showed a significant interaction (F10,36 =
4.171, p = 0.0007) between anesthetic treatment and
Mdivi-1 pre-treatment, indicating that these two condi-
tions play an interdependent role in mitochondrial
morphology. Quantification of mitochondrial morphology
(Fig. 3g) showed a robust increase in fragmented mito-
chondria in desflurane (49.2 % ± 12.0 %, p = 0.0098, n = 38
cells), as compared to the control (17.7 % ± 2.0 % n = 61
cells). Sevoflurane increased the percentage of cells
Fig. 2 Sevoflurane and desflurane reduced co-localization of pre- and postsynaptic proteins. (a–i) Confocal images stained for postsynaptic PSD-95 (green)
and presynaptic synaptophysin (red) in neurons 10 days post-culture exposed to sevoflurane and desflurane. (j) Quantification of number of PSD-95/
synaptophysin positive puncta per μm of neurite. (k) Quantification of the mean fluorescence intensity of neurons stained for either PSD-95 or
synaptophysin, normalized to the value in the control dish. One-way ANOVA: * p< 0.05, ** p< 0.01 as determined by pairwise comparison of the post-hoc
tests. No asterisk indicates no statistical significance (p> 0.05). Scale bar 10 μm
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exhibiting fragmented mitochondria (31.6 % ± 3.3 % n =
66 cells), but this difference was not significant. Our data
also revealed that fluorescence intensity – a measure of
mitochondrial membrane potential – in separate whole
images with similar densities was significantly reduced as
analyzed by a two-way ANOVA with a significant
interaction between Mdivi-1 pre-treatment and anesthetic
treatment (F2,33 = 4.421, p = 0.0199), which indicates that
Mdivi-1 pre-treatment effects depend upon whether the
cells were exposed to either sevoflurane, desflurane, or no
anesthetic. This significant reduction was shown in both
sevoflurane and desflurane treated neurons (Fig. 3h).
Fig. 3 Sevoflurane and desflurane impaired mitochondrial morphology and function, which was rescued by a mitochondrial division inhibitor, Mdivi-1.
(a-f) Confocal images of individual neurons stained with MitoTracker Red after exposure to the indicated anesthetics in the presence or absence of Mdivi-1
(10 μM) at 6 days post-culture. Arrows indicate neurites, wherever unclear. (g) Quantification of predominant mitochondrial morphology in each treatment
condition. (h) Quantification of mean fluorescence intensity of MitoTracker Red. (i) Quantification of mean fluorescence intensity of MitoTracker Red in
neurite as measured in 70 μm2 regions of interest. Two-way ANOVA. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p < 0.0001 as determined by pairwise
comparison of the post-hoc tests. Scale bar 10 μm (a–f)
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Specifically, relative to the fluorescence in the control,
desflurane (0.37 ± 0.04, n = 10) and sevoflurane (0.31 ±
0.02, n = 9) reduced mean fluorescence significantly (p <
0.0001 for both). Since there appeared a noticeable reduc-
tion in mitochondrial staining within the neurites, a
70 μm2 region of interest located at the neurite connec-
tion to the cell body was selected and the fluorescence
intensity was measured within this region of interest
(Fig. 3i). Accordingly, as before, analysis by a two-way
ANOVA showed a significant interaction between Mdivi-
1 pre-treatment and anesthetic treatment (F2,63 = 10.21,
p = 0.0001). Specifically, desflurane treated neurites exhi-
bited reduced relative fluorescence staining (0.27 ± 0.024,
n = 13 neurites p < 0.0001), as did sevoflurane treated
neurons (0.31 ± 0.044, n = 13 neurites p < 0.0001) when
compared to control neurites.
The above experiments clearly demonstrated that
sevoflurane and desflurane induced mitochondria frag-
mentation and reduced fluorescence intensity. We next
examined whether pharmacological inhibition of mito-
chondria division by a mitochondrial division inhibitor,
Mdivi-1, could reduce anesthetic-induced changes in
their morphology. Mdivi-1 was chosen since it is known
to protect neuronal cell death, and it inhibits mitochon-
drial fragmentation [15]. To this end, neurons isolated
from rat pups were first pre-treated with Mdivi-1
(10 μM [16], approximately the IC50 for this compound)
for 1 h before anesthetic exposure. MitoTracker Red
staining and confocal microscopy studies showed that
Mdivi-1 pretreatment prevented anesthetic induced
changes in mitochondrial morphology (Fig. 3e–g) as well
as fluorescent intensity (Fig. 3h, i). Figure 3e, f clearly
show that mitochondria in neurons exposed to sevoflur-
ane and desflurane still displayed rod shapes which were
distinct from the fragmented morphology seen in neu-
rons without Mdivi-1 pretreatment (Fig. 3b, c). Add-
itionally, quantification of mitochondrial morphology
(Fig. 3g) showed that Mdivi-1 pre-treatment restored
mitochondrial morphology for sevoflurane and desflur-
ane treated cells to values near control. Specifically, the
percentage of cells exhibiting fragmented mitochondria
was 15.1 % ± 1.3 % (n = 39 cells) in control, 13.8 % ±
2.1 % (n = 46 cells) in sevoflurane, and 15.9 % ± 1.2 % in
desflurane (n = 42 cells) treated cells (Fig. 3h). Similarly,
other analyses revealed that Mdivi-1 treatment increased
the relative fluorescence values as compared to similar
anesthetic treatment without Mdivi-1 pre-treatment
(Fig. 3h) for desflurane (1.01 ± 0.06, n = 4, p < 0.0001)
and for sevoflurane (0.79 ± 0.09, n = 5, p = 0.0018). Fur-
thermore, the reduction in neurite fluorescence intensity
by anesthetics was also altered by pretreatment with
Mdivi-1. Specifically, the neurites of Mdivi-1 treated
cells that were also exposed to desflurane (0.53 ± 0.057,
n = 10 neurites) and sevoflurane (0.046 ± 0.13, n = 8
neurites) were not significantly lower than Mdivi-1
treated controls cells (Fig. 3i). However, it is important
to note that the reduction in the MitoTracker fluores-
cence in neurites of Mdivi-1 pre-treated control and
anesthetic treated cells appears to be a result of the re-
duction in the control fluorescence (as revealed by
ANOVA post hoc analysis) as compared to Mdivi-1 con-
trol neurites (p = 0.0068). In addition, Mdivi-1 did not
significantly increase the fluorescence within the neur-
ites for either sevoflurane or desflurane (p > 0.05) when
compared to sevoflurane or desflurane alone. These data
indicate that Mdivi-1 impacted neurite fluorescence in-
tensity in a way that did not restore these values to
Mdivi-1 untreated controls, as it did over the whole
image fluorescence.
Mdivi-1 attenuated sevoflurane and desflurane-mediated
changes in neurite growth
If anesthetic-induced neurotoxicity were directly related
to impairment of mitochondrial integrity and function,
then protecting the mitochondria should attenuate
anesthetic-induced alterations. To test this possibility,
cells were pre-treated either with or without Mdivi-1
(10 μM) for 1 h prior to anesthetic exposure. Phase con-
trast images taken on day 3 post-culture demonstrated
that sevoflurane (Fig. 4b) and desflurane (Fig. 4c) com-
promised growth as compared to control (Fig. 4a); these
morphological alterations were absent in Mdivi-1-
pretreated neurons exposed to either sevoflurane (Fig. 4e)
or desflurane (Fig. 4f ). To confirm these observations in
the phase contrast images, we stained cells with poly-
clonal antibodies against the 160 kDa fragment of neuro-
filament (Fig. 4g–l). Reductions in the total extent of
neurite growth were qualitatively noted. We then ana-
lyzed these images (minimum n = 10 areas) using auto-
mated neurite tracing software (NeuriteTracer [17],
Fig. 4m). Areas of 0.41 mm2 were imaged and the total
neurite length based on identical threshold values for
each condition was measured. We noted a dramatic re-
duction when analyzed by a two-way ANOVA for the
anesthetic treatment (main effect F2,61 = 8.879, p =
0.0004), growth was then enhanced by Mdivi-1 pre-
treatment alone (main effect F1,61 = 24.37, p < 0.0001).
There was a non-significant Mdivi-1 pre-treatment and
anesthetic treatment interaction (F2,61 = 1.970, p =
0.1482). Specifically, the total neurite length in sevoflur-
ane was 4354 ± 461 μm (p = 0.029) and in desflurane was
3479 ± 305 μm (p = 0.012), which were significantly re-
duced as compared to that in control images (7984 ±
738 μm). In Mdivi-1 pre-treatment conditions these
values were near control values (10371 ± 1331 μm) for
both desflurane (9067 ± 1395 μm) and sevoflurane (7066
± 814 μm) (Fig. 4m).
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Sevoflurane and desflurane impaired functional synaptic
development, which is rescued by Mdivi-1 pre-treatment
We have shown that sevoflurane and desflurane caused
cellular damage by affecting synaptic machinery and
mitochondria. We next asked if these structural alter-
ations could lead to functional network abnormalities,
and if pretreatment with Mdivi-1 might improve the de-
velopment of a neuronal network. Specifically, we tested
whether anesthetics affect spontaneous synaptic current
development in pyramidal neurons, which are implicated
in cognitive functions. To this end, a pyramidal neuron
was identified based on its distinct morphological char-
acteristics in culture, namely a triangular shaped cell
body with a prominent apical dendritic process and sev-
eral shorter basal dendrites [18]. Whole cell voltage-
clamp experiments were performed on neurons with
and without pretreatment with Mdivi-1 at 10–14 days
post-culture. On each recording day, one dish from each
condition was recorded to balance possible time-
dependent changes. Spontaneous inward currents were
isolated in TTX-containing external solution at a hold-
ing potential at −70 mV. Sample traces of control, sevo-
flurane and desflurane with and without Mdivi-1 are
illustrated in Fig. 5, and the quantification of synaptic
current frequency and amplitude data is shown in Fig. 6.
The mean peak amplitudes of synaptic currents were
Fig. 4 Sevoflurane and desflurane inhibit neurite growth, which is restored with Mdivi-1 pre-treatment. (a–f) Phase contrast images of neurons
after exposure to the indicated anesthetics in the presence or absence of Mdivi-1 at 3 days post-culture. (g–l) Confocal microscopy images of
areas stained with 160 kDa neurofilament polyclonal antibodies. (m) Quantification of neurofilament staining with automated neurite tracing soft-
ware, NeuriteTracer. Two-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001 as determined by pairwise comparison of the post-hoc tests. Scale bar
25 μm (a–f), 100 μm (g–l)
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not significantly changed as analyzed by two-way
ANOVA for either Mdivi-1 pre-treatment (main effect
F1,65 = 7.232, p = 0.0694), or sevoflurane or desflurane
treatment (main effect F2,65 = 2.002, p = 0.1433). In
addition, the Mdivi-1 pre-treatment and anesthetic treat-
ment interaction F2,65 = 1.109, p = 0.5954 was not signifi-
cant (Fig. 6a). Specifically, the mean peak amplitudes in
non-Midi-1 treated neurons were 6.2 ± 0.58 (control, n
= 15), sevoflurane (5.27 ± 0.43, n = 12, p > 0.05), desflur-
ane (5.2 ± 0.32, n = 14, p > 0.05), and in Mdivi-1-treated
group were 6.49 ± 0.24 (control, n = 13), sevoflurane
(6.43 ± 0.35, n = 9, p > 0.05) and desflurane (5.74 ± 0.28,
n = 7, p > 0.05). To further test whether anesthetic treat-
ment may affect the amplitude distribution of spontan-
eous synaptic currents (despite having similar means)
these data were further analyzed using cumulative prob-
ability functions as shown in Fig. 6b. Indeed, the data
shows that each condition has a slightly different ampli-
tude distribution. In fact, when analyzed with the
Kolmogorov-Smirnov test each condition’s cumulative
probability function was significantly different: sevoflur-
ane compared to control +Mdivi-1 was p = 0.0040 and
all others were p < 0.0001. Since the Kolmogorov-
Smirnov test tests whether the median, variance, or
shape of cumulative probability functions are different,
these results indicate that although the mean amplitudes
did not change (Fig. 6a), the distribution of all amplitude
events was slightly different among different treatment
conditions. All traces, except for sevoflurane +Mdivi-1
and desflurane +Mdivi-1, were entirely shifted to the left
of the control trace, indicating that there was a some-
what larger probability of smaller amplitude, spontan-
eous synaptic currents in these conditions. Interestingly,
both sevoflurane and desflurane with Mdivi-1 pre-
treatment was shifted to the right of the control trace
for low amplitude events, indicating these conditions
had a reduced frequency of low amplitude events.
The mean frequency of spontaneous events was evi-
dently altered by both sevoflurane and desflurane
(Fig. 6c, d). The spontaneous inward currents in control
pyramidal neurons (Fig. 5a) were robust, indicating the
development of a functional network, while both sevo-
flurane and desflurane (Fig. 5c–e; Fig. 6c, d) reduced the
frequency of these synaptic currents. Interestingly, the
reduction in the frequency of synaptic events was res-
cued by pretreatment of neurons with Mdivi-1 (Fig. 5d–
f; Fig. 6c, d). This was analyzed with a two-way ANOVA,
which showed a significant Mdivi-1 pre-treatment and
anesthetic treatment interaction (F2,64 = 3.286, p =
0.0438), indicating again that Mdivi-1 pre-treatment ef-
fects depend whether the cells were exposed to
anesthetic or not. Specifically, the mean synaptic fre-
quency in control neurons was 1.12 ± 0.09Hz (n = 15),
which was reduced to 0.65 ± 0.06Hz (n = 12, p = 0.0081)
by sevoflurane, and to 0.5 ± 0.06Hz (n = 14, p < 0.0001)
by desflurane (Fig. 6c). In the Mdivi-1 pre-treatment
group, the mean frequency in control neurons was 1.04
± 0.13Hz (n = 13), 0.93 ± 0.07Hz (n = 9, p > 0.05) in sevo-
flurane treated neurons and 0.92 ± 0.16Hz (n = 7, p >
0.05) in desflurane exposed neurons (Fig. 6c), respect-
ively. To further evaluate the effects of Mdivi-1 on the
distribution of spontaneous synaptic currents, we plotted
the interevent interval of each current in a cumulative
probability plot (Fig. 6d). We then analyzed these cumu-
lative probability plots for statistical significance with the
Kolmogorov-Smirnov test. Sevoflurane (p < 0.0001), and
desflurane (p < 0.0001) cumulative probability functions
were dramatically shifted to the right, as compared to
the control trace, which indicates there was a dramatic
increase in the interevent interval in both anesthetic
treated conditions. Furthermore, Mdivi-1 pre-treatment
shifted the cumulative probability of the interevent inter-
val to the left, as compared to non-Mdivi-1 treated cells
with similar anesthetic exposure, for both sevoflurane (p
= 0.008) and desflurane (p < 0.0001), indicating a restor-
ation towards a distribution comprising more frequent
short interevent intervals, as seen in control. However,
Mdivi-1 pre-treatment of sevoflurane resulted in a cu-
mulative probability function that was still significantly
different than that of the control (p < 0.0001) –
Fig. 5 Sevoflurane and desflurane reduced spontaneous synaptic events
and these effects were rescued by pre-treatment with Mdivi-1. (a–f)
Representative patch clamping recording traces of spontaneous synaptic
currents in neurons exposed to no anesthetic (control), desflurane, and
sevoflurane alone or with Mdivi-1 (10 μM) pre-treatment, as indicated,
recorded at 10 days post-culture. Spontaneous synaptic currents were
isolated by adding tetrodotoxin (0.5 μM) in external solution
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indicating that Mdivi-1 pre-treatment resulted in a dis-
tribution that significantly differed not in mean (Fig. 6c),
but rather the shape of the probability function was not
fully restored to that of control. Meanwhile, Mdivi-1
pre-treated control traces were not different than non-
treated control traces (p = 0.0762).
Discussion
This study provides the first integrative evidence on the
molecular and functional effects of sevoflurane and des-
flurane on the developing neural circuitry in rats. We
have also provided the first direct evidence that Mdivi-1,
a mitochondrial protective agent, may hold potential to
improve some, but not all, of the negative effects of des-
flurane and sevoflurane on neurons in culture.
In recent years, concerns have been raised regarding
neurotoxic side effects of anesthetic exposure in young
children; these effects have since been linked to neuro-
cognitive and behavioral deficits [2, 6]. Limited data
however exist for the effects of anesthetics on the mole-
cules and mechanisms that underlie synapse formation
and plasticity. This information is critical because devel-
oping neurons and their synaptic connectivity is in turn
contingent upon neuronal firing patterns during a crit-
ical period; the silencing of which is the prime target of
anesthetic actions. Perturbation of neuronal activity,
even over a short time period, is likely to have a long-
term impact on neuronal connectivity, which forms the
basis for cognitive functions In this study, we provided
an account of the effects of two extensively used volatile
anesthetic agents and found sevoflurane and desflurane
to compromise the development of functional synapses.
Specifically desflurane, but not sevoflurane, significantly
reduced the level of the critical presynaptic protein
synaptophysin. Concurrently, both sevoflurane and des-
flurane reduced the density of synaptic protein puncta
along neurites. As a result, both sevoflurane and desflur-
ane reduced the frequency of spontaneous synaptic
Fig. 6 Statistical data depicting the effects of sevoflurane and desflurane with and without Mdivi-1 pretreatment on the amplitude and frequency
of spontaneous synaptic events. The mean spontaneous current amplitude was quantified in (a), and a cumulative probability plot of the event
amplitude (pA) of all events recorded (minimum 400 events) in (b). Quantification of mean spontaneous current frequency (c) and a cumulative
probability plot of the interevent interval (ms) of all events recorded (minimum 400 events) (d). Two-way ANOVA. * p < 0.05, ** p < 0.01, ***
p < 0.001, **** p < 0.0001 as determined by pairwise comparison of the post-hoc tests; cumulative probability plot analyzed with
Kolmogorov-Smirnov test
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currents. Previous studies in animal models have re-
vealed that the loss of synaptophysin or PSD-95 in the
cortex results in cognitive decline and behavioral deficits
[19–21]. Indeed, exposure to 2.5 % sevoflurane in mice
during the early stages of neuronal development results
in learning and memory deficits that are accompanied
by reduced PSD-95 protein expression in the hippocam-
pus [22]. These data are consistent with our observa-
tions in developing rat cortical neurons. Together, these
data provide preliminary insights into a potential mech-
anism involving synaptic proteins by which anesthetics
may lead to long-term cognitive impairments. However,
our study highlights that the effects of general anes-
thetics go beyond those that can be explained by transi-
ent disruptions in neural activity and communication,
since our cultures were exposed to anesthetic prior to
the formation of synapses.
Interestingly, the cellular targets of general anesthetics
are yet to be fully understood, which may underlie their
neurotoxicity. It is known that the mechanism of action
of general anesthesia involves targeting ligand-gated ion
channels (e.g. receptors of NMDA, GABAA, nACh, sero-
tonin etc.), voltage-gated ion channels (e.g. sodium, po-
tassium, calcium etc.), and background channels (e.g.
two pore domain potassium channels) to induce
anesthesia [3, 23–25]. Although the activities of these re-
ceptors and ion channels play important roles in neurite
outgrowth, synaptic transmission, and plasticity, it is un-
likely that anesthetic targeting of only one of these fac-
tors could suffice to account for all aspects of their
clinical toxicity. In addition, the distribution and
localization of these channels in different neurons and
brain regions are widely diverse and the effects of anes-
thetics may often be transient and reversible upon
anesthetic removal. It is therefore unlikely that
anesthetic neurotoxicity involves these channels only.
Neurite outgrowth, synaptic transmission, and plasticity
rely critically on intracellular energy sources. Therefore,
it stands to reason that shutting down mitochondrial
function may impair all of the above processes, creating
a cascade of events, which could lead to neurodegenera-
tion. Mitochondria dysfunction has been implicated in a
variety of neurodevelopmental and genetic disorders
[26]. Mitochondrial dynamics include fission and fusion,
and mitochondrial fission has been closely linked to
apoptotic pathway [27]. Indeed, emerging evidence indi-
cates that anesthetic neurotoxicity may involve changes
in internal organelles including the mitochondria [28,
29]. For instance, general anesthetics (isoflurane, nitrous
oxide, and midazolam) alone, or in combination, cause
chronic impairment of mitochondria morphogenesis and
synaptic transmission in the developing rat brain [30].
Consistent with these studies, our data clearly demon-
strate that both desflurane and sevoflurane trigger
mitochondria fragmentation leading to impairment of
functional synapse development. Interestingly, we also
demonstrated that pre-treatment of in vitro cortical
neuron cultures with Mdivi-1 prior to anesthetic expos-
ure significantly attenuated their effects on neural
growth (Fig. 4), synaptic currents (Figs. 5 and 6), as well
as mitochondrial integrity (Fig. 3).
Mdivi-1 is a highly efficient and selective inhibitor of the
mitochondrial division protein Drp1. It inhibits mitochon-
drial division by binding to Drp1, preventing a conform-
ational change that allows Drp1 self-assembly and GTP
hydrolysis, resulting in the formation of “netlike” mito-
chondria [16]. It has been further shown that Mdivi-1
reduces apoptosis by inhibiting mitochondrial outer mem-
brane permeability in vivo and blocks Cytochrome c
release in vitro [16]. Recent studies have proven the neu-
roprotective effects of Mdivi-1 against glutamate excito-
toxicity and oxygen-glucose deprivation in vitro and
ischemic brain injury in vivo [31]. Mdivi-1 has also been
found to protect against doxorubicin-induced cardiotoxi-
city [32] and pilocarpine-induced seizures in rat hippo-
campal neurons [33]. In this study, we revealed that pre-
treatment with Mdivi-1 effectively inhibits sevoflurane
and desflurane-triggered cell damage and synapse attenu-
ation. There exists other evidence supporting potential
neuroprotective strategies against anesthesia-induced
toxicity in the developing brain. For instance, Pramipex-
ole, a drug known to protect mitochondrial integrity, was
found to prevent cognitive decline from early anesthesia
exposure in rats [34]. Antioxidant agents such as lPPX
and EUK-134 have also been demonstrated to prevent
anesthetic-induced changes in mitochondrial integrity and
cognitive dysfunction [34]. Taken together, it would ap-
pear that strategies targeting mitochondrial structure and
function might offer a therapeutic approach against
anesthetic-induced neuronal cytotoxicity.
Conclusions
In summary, our data support the notion that inhala-
tional anesthetics perturb developing neural circuits dur-
ing critical periods of synaptogenesis. This perturbation
of synaptic architecture and function may partly contrib-
ute to the behavioral deficits observed in neonatal rat or
mouse models after exposure to anesthetics [35, 36].
Our study, together with others, underscores the import-
ance of cautious use of desflurane and sevoflurane in
clinical settings – especially in infants and pregnant
women when the central nervous system of babies is
undergoing rapid development. In addition, the data pre-
sented here suggest that mitochondria are likely one of
the main cellular targets for anesthetic neurotoxicity.
Future strategies should involve exploring various pro-
tective roles of pharmacological agents, such as Mdivi-1,
at both the cellular, and behavioral levels.
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Methods
Rat cortical neuronal culture and anesthetic exposure
All animal procedures were in accordance with the stan-
dards established by the Canadian Council on Animal
Care and with the University of Calgary Animal Care
and Use Policy.
Sprague-Dawley rat frontal cortexes were removed
from postnatal day 0 pups and enzymatically dissociated
with papain (50 u/mL). Cells were then triturated with
glass pipettes of decreasing size to create a suspension of
single cells. Cells were then diluted to an appropriate
density in culture media and plated on culture dishes
with a glass coverslip coated with laminin (2 μg/mL) and
poly-D-lysine (30 μg/mL). Cells were allowed to settle
for one hour prior to the addition of additional 2 mL of
culture medium. The culture medium used was Neuro-
basal medium supplemented with 2 % B27, L-Glutamine
(200 mM), 4 % FBS, and penicillin-streptomycin (Invi-
trogen), which was changed (50 % removed and re-
placed) every 3–4 days. Culture dishes were allowed to
settle for an additional 1–2 hours prior to being placed
in an airtight modular incubator chamber (Billups-
Rothenberg). Anesthesia-medical air gas mixtures were
vaporized using a Datex-Ohmeda Aestiva/5 vaporizer
and concentrations were monitored with a GE Health-
care Gas Analyzer. Controls for each exposure group
consisted of cells that were incubated in the same man-
ner with medical air only. After 1 h of exposure, the
neurons were placed back and maintained in an incuba-
tor (37 °C, 5 % CO2) until use.
Cell viability assay
The effects of sevoflurane and desflurane on cell viability
were tested in developing neurons at day 3 post-culture
to avoid the proliferation of glia seen in later cultures
that may mask apoptotic effects in neurons. Both the
control and anesthetic-exposed groups were evaluated
using the LIVE⁄DEAD® Viability⁄Cytotoxicity Kit (Mo-
lecular Probes). Specifically, the cells were exposed to
calcein-AM (green, live cells) and ethidium homodimer-
1 (red, dead cells) dyes at room temperature for 15 min.
These preparations were observed under confocal mi-
croscopy (LSM 510 Meta, Zeiss) via a 20X objective at
488 nm (green) and 548 (red) excitation wavelength.
Fluorescence images (area size of 88,090 μm2) were col-
lected using a long pass filter (505 nm), and band pass
filter (560–615 nm) for green and red, respectively. The
number of live (green) or dead (red) cells were viewed
and counted manually using ImageJ software.
Immunocytochemistry and confocal microscopy
Immunostaining study of synaptic protein markers and
neuronal cytoskeleton was conducted on cells in culture
for at least 10 days to allow for the development of a
network and maturation of synaptic components [14].
Fixation was performed with 4 % paraformaldehyde and
15 % picric acid fixative solution for 1 h at room
temperature. The fixed cultures were permeabilized for
1 h with incubation media consisting of 0.1 % Triton X
with 5 % goat serum. A primary rabbit monoclonal anti-
body for synaptophysin (1:500 dilution) (Abcam) and
mouse monoclonal antibody for PSD-95 (1:2000 dilu-
tion) (NeuroMab) were applied to the cultures overnight
at 4 °C. Secondary antibodies of AlexaFluor 488 goat
anti-mouse IgG (1:200 dilution) (Invitrogen) and Alexa-
Fluor 546 goat anti-rabbit (1:200 dilution) (Invitrogen)
were then applied. Dishes were mounted with MOWIOL
mounting media with DAPI to stain nuclei (Sigma-Al-
drich). A similar procedure was followed for the staining
of neurofilament, with the exception of the types of pri-
mary and secondary antibodies used. A chicken poly-
clonal antibody against the 160 kDa fragment of
neurofilament (1:500 dilution) (Novus Biologicals) was
applied to the cultures after permeabilization. The sec-
ondary antibody of AlexaFluor 488 goat anti-chicken
(1:200 dilution) was applied to the cultures after washing
off the primary antibody. Negative control experiments
were performed at the same time to test the specificity
of synaptophysin, PSD-95, and neurofilament antibodies.
No immunofluorescence was detected when primary
antibodies were excluded from the staining procedures
(data not shown). Image acquisition parameters (laser
intensity, pinhole sizes, exposure times, gain settings
etc.) were kept the same for both control and anesthetic
treated neurons.
To assess the impact of anesthetics on the integrity and
function of mitochondria, cortical cultures at 4 days post-
culture had their media replaced with warm Hanks’
Balanced Salt Solution with HEPES (10 mM), L-glutamine
(2 mM), and succinate (100 μM). MitoTracker Red
CMXRos (200 nM) containing HBSS medium was then
incubated with the cells for 15 mins at 37 °C. Cells were
imaged at this time point to minimize the impact of glia
proliferation that would complicate neuron identification.
The percentage of cells that exhibited a given mitochon-
drial morphology (fragmented, intermediate, fused) was
counted in triplicate experiments. Each cell was classified
as having a given mitochondrial morphology based on
the predominant mitochondrial morphology present
in each cell according to the following criteria: mito-
chondria were considered fragmented when less than
0.75 μm in length, intermediate when 0.75 μm to
3 μm in length, and fused when greater than 3 μm in
length.
Fluorescence images were taken with a Nikon Eclipse
C1Si confocal microscope (Nikon Instruments Inc.).
Fluorescent intensity was measured exclusively in separate
Xu et al. Molecular Brain  (2016) 9:35 Page 11 of 13
image sets taken with identical confocal parameters for all
treatment conditions. Fluorescence intensity was mea-
sured over the entire field of view with similar cell dens-
ities (approx. 1000 cells/mm2) for each fluorescent dye
used. Fluorescence units were standardized (“relative
fluorescence ratio”) to control images taken from the same
culture that were fixed and stained at identical time
points.
Whole-cell patch clamp recording of synaptic currents
Whole-cell recordings of spontaneous synaptic currents
were performed on pyramidal cortical neurons after
10 days (to correlate with synaptic protein staining) in
culture using a Multiclamp 700B amplifier connected to
an analog-to-digital interface Digidata 1322 (Axon
Instruments). Signals were recorded with pClamp 9.2
software (Axon Instruments) under voltage-clamp mode
with a holding potential of −70 mV. The external solu-
tion contained (in mM) NaCl, 135; CaCl2, 3; KCl, 5;
MgCl2, 2; HEPES, 10; D-Glucose, 10; pH adjusted to 7.3
with NaOH; ~ 330 mOsm, this solution included tetro-
dotoxin (TTX, 0.5 μM) in order to block action
potential-dependent synaptic events. The internal pip-
ette solution was composed of (in mM) CsCl, 140;
CaCl2, 1; MgCl2, 2; HEPES, 10; EGTA, 11, ATP-Mg, 2;
GTP-Na, 0.6; pH adjusted to 7.3 with CsOH; ~
300 mOsm. Borosilicate patch pipettes (A-M Systems,
Inc) pulled to a tip resistance of 3–5 MΩ were exclu-
sively used. Only cells with a series resistance less than
~15 MΩ and leak currents less than ~100 pA were
included.
Statistical analysis
Spontaneous events were analyzed with Mini Analysis
software (Synaptosoft). Peaks of events were visually
screened and selected if they displayed a monophasic
rise time to peak, an amplitude larger than the detection
threshold (>5 pA) set at the maximum of the back-
ground noise. Synaptic events, acquired for 100 s after
the initial 1–2 min of recording of basal activity, were
used for frequency and amplitude analysis.
Statistical significance test was run using OriginPro
8.0 PRO or GraphPad. One-way ANOVA was used to
compare groups with only one factor (ie. anesthetic ex-
posure). Two-way ANOVA was used to compare groups
with two factors (ie. anesthetic exposure and Mdivi-1
treatment). Post-hoc tests with Bonferroni test were con-
ducted. A square root transform was applied to the
mean frequency and mean peak amplitude of spontan-
eous events to stabilize changes in variance as a conser-
vative approach to the violation of homogeneity in order
to perform ANOVA. Data shown was not transformed.
Cumulative synaptic event plots were tested for statis-
tical significance with the Kolmogorov-Smirnov test.
Values were graphed as mean ± S.E.M. Differences be-
tween data sets were considered significant if appropri-
ate statistical tests resulted in p values smaller than 0.05;
p values were reported for the post-hoc tests, except
where indicated otherwise.
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